What is claimed is:

~~1. Pirfenidone for use in treating a patient in need of pirfenidone therapy, characterized in that the treating comprises avoiding or discontinuing concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2) to avoid reduced exposure to pirfenidone.~~

~~2.~~1. Use of pirfenidone in the manufacture of a medicament for treating a patient in need of pirfenidone therapy, characterized in that the treating comprises avoiding or discontinuing concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2) to avoid reduced exposure to pirfenidone.

~~3.~~2. The ~~pirfenidone or~~ use of claim 1 ~~or 2~~, comprising avoiding concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2).

~~4.~~3. The ~~pirfenidone or~~ use of claim 1 ~~or 2~~, comprising discontinuing a strong inducer of cytochrome P450 1A2 (CYP1A2) prior to or concurrent with starting pirfenidone therapy to avoid reduced exposure to pirfenidone.

~~5.~~4. The ~~pirfenidone or~~ use of claim 1 ~~or 2~~, wherein the patient is a smoker who is discontinuing smoking to avoid reduced exposure to pirfenidone.

~~6.~~5. The ~~pirfenidone or~~ use of claim ~~5~~4, wherein the patient is discontinuing smoking within 4 weeks prior to the administration of pirfenidone.

~~7.~~6. The ~~pirfenidone or~~ use of claim ~~6~~5, wherein the patient is discontinuing smoking concurrent with the start of administration of pirfenidone.

~~8.~~7. The ~~pirfenidone or~~ use of claim 1 ~~or 2~~, wherein the patient is a smoker and avoids smoking when using pirfenidone.

~~9. Pirfenidone for use in treating a patient in need of pirfenidone therapy, characterized in that the treating comprises using caution with concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2) to avoid reduced exposure to pirfenidone.~~

~~10.~~8. Use of pirfenidone in the manufacture of a medicament for treating a patient in need of pirfenidone therapy, characterized in that the treating comprises using caution with concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2) to avoid reduced exposure to pirfenidone.

~~11.~~9. The ~~pirfenidone or~~ use of any one of claims 1 to ~~4~~3 and ~~9 to 10~~8, wherein the inducer of a CYP1A2 is rifampin.

~~12.~~10. The ~~pirfenidone~~ use of any one of claims 1 to ~~4~~3 and ~~9 to 10~~8, wherein the inducer of CYP1A2 is cigarette smoke.

~~13.~~11. The ~~pirfenidone or~~ use of any one of claims 1 to ~~12~~10, wherein the patient has idiopathic pulmonary fibrosis.

~~14.~~12. The ~~pirfenidone or~~ use of any one of claims 1 to ~~13~~11, wherein the patient suffers from a disease selected from pulmonary fibrosis, idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, autoimmune lung diseases, benign prostate hypertrophy, coronary or myocardial infarction, atrial fibrillation, cerebral infarction, myocardiac fibrosis, musculoskeletal fibrosis, post-surgical adhesions, liver cirrhosis, renal fibrotic disease, fibrotic vascular disease, scleroderma, Hermansky-Pudlak syndrome, neurofibromatosis, Alzheimer's disease, diabetic retinopathy, or skin lesions, lymph node fibrosis associated with HIV, chronic obstructive pulmonary disease (COPD), inflammatory pulmonary fibrosis, rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; gout, an arthritic condition; sepsis; septic shock; endotoxic shock; gram-negative sepsis; toxic shock syndrome; myofacial pain syndrome (MPS); Shigellosis; asthma; adult respiratory distress syndrome; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; glomerular nephritis; scleroderma; chronic thyroiditis; Grave's disease; Ormond's disease; autoimmune gastritis; myasthenia gravis; autoimmune hemolytic anemia; autoimmune neutropenia; thrombocytopenia; pancreatic fibrosis; chronic active hepatitis including hepatic fibrosis; acute or chronic renal disease; renal fibrosis; diabetic nephropathy; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke or ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute or chronic pain; allergies, allergic rhinitis; allergic conjunctivitis; cardiac hypertrophy, chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synoviitis; muscle degeneration, bursitis; tendonitis; tenosynoviitis; herniated, ruptured, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; silicosis; pulmonary sarcosis; bone resorption disease, osteoporosis; multiple myeloma-related bone disorder; cancer, metastatic breast carcinoma, colorectal carcinoma, malignant melanoma, gastric cancer, non-small cell lung cancer; graft-versus-host reaction; auto-immune disease, multiple sclerosis, lupus; fibromyalgia; AIDS; Herpes Zoster, Herpes Simplex I or II, influenza virus, Severe Acute Respiratory Syndrome (SARS); cytomegalovirus; or diabetes mellitus, proliferative disorders, acute myelogenous leukemia, chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma, multiple myeloma, breast cancer,; bone metastases; pain disorders; neuromuscular pain, headache, cancer pain, dental pain, arthritis pain; angiogenic disorders; including solid tumor angiogenesis, ocular neovascularization, infantile hemangioma;

edema, fever, analgesia, ~~;~~ organ hypoxia; thrombin-induced platelet aggregation; or protozoal diseases.

~~15.~~13. The ~~pirfenidone or~~ use of any one of claims 1 to ~~14~~12, wherein the pirfenidone is administered at a total daily dose of 1 mg/kg to 40 mg/kg per day.

~~16.~~14. The ~~pirfenidone or~~ use of any one of claims 1 to ~~14~~12, wherein the pirfenidone is to be administered at a total daily dosage of at least 1800 mg.

~~17.~~15. The ~~pirfenidone or~~ use of any one of claims 1 to ~~14~~12, wherein the pirfenidone is to be administered at a total daily dosage of 2400 mg or 2403 mg.

~~18.~~16. The ~~pirfenidone or~~ use of any one of claims 1 to ~~14~~12, wherein each dose of pirfenidone to be administered is 801 mg.

~~19.~~17. The ~~pirfenidone or~~ use of any one of claims 1 to ~~18~~16, wherein pirfenidone is to be administered three times a day.

~~20.~~18. The ~~pirfenidone or~~ use of any one of claims 1 to ~~19~~17, wherein pirfenidone is to be administered with food.

~~21.~~19. A package or kit comprising (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling comprising avoiding or discontinuing concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2), and optionally according to any one of claims 1-~~20~~18.